Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study

被引：0
|
作者：
Yao, B. [1 ]
Yang, L. F. [1 ]
Ran, T. [1 ]
Deng, S. [1 ]
Xu, Q. [1 ]
机构：
[1] Tongren City Peoples Hosp, Tongren, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
osimertinib; aumolertinib; safety intolerant;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-63
引用
收藏
页码：S666 / S667
页数：2
相关论文
共 50 条
  • [31] Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study
    Zhou, Bin
    Gong, Qiang
    Li, Ben
    Qie, Hai-Ling
    Li, Wei
    Jiang, Hong-Tao
    Li, He-Fei
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (05) : 643 - 651
  • [32] Aumolertinib in Treatment-Naive EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY
    Zhang, X.
    Zhang, M.
    Wei, C.
    Du, X.
    Zhang, G.
    Niu, Y.
    Yan, X.
    Yang, J.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S194 - S194
  • [33] Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
    Ji, Jingran
    Aredo, Jacqueline, V
    Piper-Vallillo, Andrew
    Huppert, Laura
    Rotow, Julia K.
    Husain, Hatim
    Stewart, Susan L.
    Cobb, Rosemary
    Wakelee, Heather A.
    Blakely, Collin Michael
    Wong, Melisa L.
    Gubens, Matthew A.
    Chen, Justin
    Oxnard, Geoffrey R.
    McCoach, Caroline Elizabeth
    Piotrowska, Zofia
    Neal, Joel W.
    Riess, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
    Watanabe, Kana
    Saito, Ryota
    Miyauchi, Eisaku
    Nagashima, Hiromi
    Nakamura, Atsushi
    Sugawara, Shunichi
    Tanaka, Nobuyuki
    Terasaki, Hiroshi
    Fukuhara, Tatsuro
    Maemondo, Makoto
    CANCERS, 2023, 15 (17)
  • [35] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [36] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [37] Immunotherapy in Patients Who Have NSCLC Without EGFR or ALK Mutations
    Gandhi, Leena
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (07) : 484 - 485
  • [38] Savolitinib Plus Osimertinib for Previously Untreated NSCLC Patients with EGFR Mutations and MetAmplification: A Case Series
    Xiao, K.
    Chu, T.
    Zhu, Y.
    Yang, S.
    Xiao, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S637 - S637
  • [39] Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib
    Duan, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
  • [40] Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)
    Okuma, Yusuke
    Shimokawa, Mototsugu
    Hashimoto, Kana
    Mizutani, Hideaki
    Wakui, Hiroshi
    Murakami, Shuji
    Atagi, Shinji
    Minato, Koichi
    Seike, Masahiro
    Ohe, Yuichiro
    Kubota, Kaoru
    FUTURE ONCOLOGY, 2022, 18 (05) : 523 - 531
12345